Meltem Karakulak Kafkas

Meltem Karakulak Kafkas

Auto-generated profile, based on publicly available information

Meltem Karakulak Kafkas

Maltepe No: 27, Family Health Center , Istanbul , Turkey

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2022 in Family Practice
Verified
Journal Article
Open access
PDF file
MKMeltem Karakulak Kafkas
Meltem Karakulak Kafkas
STSabah Tuzun
Sabah Tuzun
NHNazlı Hacıağaoğlu
Nazlı Hacıağaoğlu
HÇHüseyin Çetin
Hüseyin Çetin
SCSevda Şener Cömert
Sevda Şener Cömert
EŞEngin Ersin Şimşek
Engin Ersin Şimşek
The effect of COVID-19 infection on pulmonary function is unknown. This study aimed to evaluate pulmonary function tests (PFTs) of patients hospitalized with the diagnosis of COVID-19 pneumonia at 3 and 6 months post-discharge. Patients aged 18 years and over who had positive COVID-19 PCR test results and were hospitalized in the pandemic service between 1 May 2020 and 31 October 2020, were included in the study. All patients were evaluated with PFTs FVC, FEV1, FEV1/FVC, and FEF25–75 at 3 and 6 months after discharge. The mean age of 34 patients included in the study was 47.7 ± 12.7 years. The FVC, FEV1, FEV1/FVC, and FEF25–75 measurements at 3 and 6 months post-discharge showed no significant difference (P = 0.765, P = 0.907, P = 0.707, and P = 0.674, respectively). There was no significant difference in any PFT measurements at the third month follow-up, regardless of the pharmacological treatment protocols applied during hospitalization (P > 0.05). However, FEV1/FVC and FEF25–75 levels were 83.1 [3.4]% and 91.0 [10.0]%, respectively, in those who received systemic steroid treatment, and 78.3 ± 8.5% and 72.5 ± 25.7% in those who did not (P = 0.019 and P = 0.048, respectively). In addition, FVC and FEV1 levels increased significantly from the third to the sixth month follow-up in patients who received systemic steroid therapy (P = 0.035 and P = 0.018, respectively). Although there is no significant difference in PFT measurements from 3 to 6 months in COVID-19 patients, systemic steroid therapy may have a beneficial effect on respiratory function in COVID-19 patients.